Rituximab therapy for primary Sjögren's syndrome: An open-label clinical trial and mechanistic analysis

Arthritis and Rheumatism

Volumn 65, Issue 4, 2013, Pages 1097-1106

  St Clair, E William ^a   Levesque, Marc C ^b   Prak, Eline T Luning ^c   Vivino, Frederick B ^c   Alappatt, Chacko J ^c   Spychala, Meagan E ^d   McNamara, James ^e   Moser Sivils, Kathy L ^f   Fisher, Lytia ^g   Cohen, Philip ^g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d RHO INC   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; CEVIMELINE; CYCLOSPORIN; DIPHENHYDRAMINE; DIPHTHERIA TETANUS TOXOID; HYDROXYCHLOROQUINE; LA ANTIBODY; METHYLPREDNISOLONE; MUSCARINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PILOCARPINE; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; RO ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; HUMAN; HUMORAL IMMUNE DEFICIENCY; LACRIMAL GLAND; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MYALGIA; OPEN STUDY; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRE B LYMPHOCYTE; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALIVARY GLAND; SJOEGREN SYNDROME; SQUAMOUS CELL CARCINOMA; SWELLING; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE COUNT; MIDDLE AGED; PROSPECTIVE STUDIES; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84875741064     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37850     Document Type: Article

References (36)

1. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR,. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004; 33: 39-43.
2. Fox RI,. Sjögren's syndrome. Lancet 2005; 366: 321-31.
3. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, et al, GEMESS Study Group. Primary Sjögren's syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87: 210-9.
4. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT,. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
5. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X,. Treatment of primary Sjögren's syndrome: a systematic review. JAMA 2010; 304: 452-60.
6. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740-50.
7. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310-7.
8. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomized, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
9. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-8.
10. Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011; 63: 1116-23.
11. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
12. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
13. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
14. Youinou P, Devauchelle-Pensec V, Pers JO,. Significance of B cells and B cell clonality in Sjögren's syndrome [review]. Arthritis Rheum 2010; 62: 2605-10.
15. Hansen A, Gosemann M, Pruss A, Reiter K, Ruzickova S, Lipsky PE, et al. Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 1897-908.
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
17. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999; 159: 174-81.
18. Talamo J, Frater A, Gallivan S, Young A,. Use of the short form (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997; 36: 463-9.
19. Abdallah KO, Luning Prak ET,. B cell monitoring of transplant patients treated with anti-CD20. Clin Transpl 2006: 427-37.
20. Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 2008; 126: 282-90.
21. Gao J, Cha S, Jonsson R, Opalko J, Peck AB,. Detection of anti-type 3 muscarinic acetylcholine receptor antibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004; 50: 2615-21.
22. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH,. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990; 87: 1663-7.
23. Sekiguichi DR, Smith SB, Sutter JA, Goodman NG, Propert K, Louzoun Y, et al. Circulating lymphocyte subsets in normal adults are variable and can be clustered into subgroups. Cytometry B Clin Cytom 2011; 80B: 291-9.
24. Waterman SA, Gordon TP, Rischmueller M,. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000; 43: 1647-54.
25. Park K, Haberberger RV, Gordon TP, Jackson MW,. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2011; 63: 1426-34.
26. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML,. B-cell stage and context-dependent requirements for survival signals from BAFF and the B cell receptor. Immunol Rev 2010; 237: 205-25.
27. Groom J, Kalled SL, Cutleer AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002; 109: 59-68.
28. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007; 56: 1464-77.
29. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC,. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-32.
30. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009; 4: 285-96.
31. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg J, Mariette X,. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007; 66: 700-3.
32. Bingham CO III, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64-74.
33. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Hachulla E, et al. Tolerance and efficacy of rituximab in primary Sjögren syndrome: final results of a randomized controlled trial [abstract]. Arthritis Rheum 2012; 64 Suppl: S1079.
34. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66: 351-7.
35. Vosslamber S, Raterman HG, van der Pouw Krann TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1153-9.
36. Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2012. E-pub ahead of print.